Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8301 to 8350 of 8904 results

  1. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 654 

    Withdrawn guidance

  2. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.  

    Withdrawn guidance

  3. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Withdrawn guidance

  4. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Withdrawn guidance

  5. Flu treatment - zanamivir, amantadine and oseltamivir (TA58)

    This guidance has been updated and replaced by NICE technology appraisal guidance 168.

    Withdrawn guidance

  6. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Withdrawn guidance

  7. Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

    This guidance has been updated and replaced by NICE technology appraisal guidance 849.

    Withdrawn guidance

  8. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

    Withdrawn guidance

  9. Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA802.

    Withdrawn guidance

  10. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Withdrawn guidance

  11. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Withdrawn guidance

  12. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.

    Withdrawn guidance

  13. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Withdrawn guidance

  14. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Withdrawn guidance

  15. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  16. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

    This guidance has been updated and replaced by NICE technology appraisal guidance 770.

    Withdrawn guidance

  17. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

    Withdrawn guidance

  18. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Withdrawn guidance

  19. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Withdrawn guidance

  20. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  21. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1119.

    Withdrawn guidance

  22. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Withdrawn guidance

  23. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Withdrawn guidance

  24. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.

    Withdrawn guidance

  25. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1120.

    Withdrawn guidance

  26. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance

  27. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

    Withdrawn guideline

  28. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).

    Withdrawn guideline

  29. DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review (NG251)

    We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See NICE review 1 on DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.

    Withdrawn guideline

  30. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

    Withdrawn guideline

  31. Preventing excess weight gain (NG7)

    This guideline has been updated and replaced by NICE guideline NG246.

    Withdrawn guideline

  32. Stop smoking interventions and services (NG92)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  33. Chronic kidney disease: managing anaemia (NG8)

    This guidance has been updated and replaced by NICE guideline NG203.

    Withdrawn guideline

  34. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

    Withdrawn guideline

  35. Smoking prevention in schools (PH23)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  36. Smoking: stopping in pregnancy and after childbirth (PH26)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  37. Weight management before, during and after pregnancy (PH27)

    The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).

    Withdrawn guideline

  38. Looked-after children and young people (PH28)

    This guidance has been updated and replaced by NICE guideline NG205.

    Withdrawn guideline

  39. Sexually transmitted infections and under-18 conceptions: prevention (PH3)

    This guidance has been updated and replaced by NICE guideline NG221.

    Withdrawn guideline

  40. Needle and syringe programmes (PH18)

    This guideline has been updated and replaced by NICE guideline PH52.

    Withdrawn guideline

  41. Workplace health: long-term sickness absence and incapacity to work (PH19)

    This guideline has been updated and replaced by NICE guideline NG146.

    Withdrawn guideline

  42. Four commonly used methods to increase physical activity (PH2)

    This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41  Physical activity: brief advice for adults in primary care (2013) PH44  Exercise referral schemes to promote physical activity (2014) PH54 

    Withdrawn guideline

  43. Social and emotional wellbeing in secondary education (PH20)

    This guideline has been updated and replaced by NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

    Withdrawn guideline

  44. Immunisations: reducing differences in uptake in under 19s (PH21)

    This guideline has been replaced by NICE guideline NG218.

    Withdrawn guideline

  45. Mental wellbeing at work (PH22)

    This guideline has been updated and replaced by NICE guideline NG212.

    Withdrawn guideline

  46. Smoking: brief interventions and referrals (PH1)

    This guidance has been updated and replaced by NICE guideline NG92.

    Withdrawn guideline

  47. Maternal and child nutrition (PH11)

    This guideline has been updated and replaced by NICE guideline NG247.

    Withdrawn guideline

  48. Smoking: preventing uptake in children and young people (PH14)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

    Withdrawn guideline

  49. Stop smoking services (PH10)

    This guideline has been updated and replaced by NICE guideline NG92.

    Withdrawn guideline

  50. Social and emotional wellbeing in primary education (PH12)

    This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

    Withdrawn guideline